SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

14 Aug 2025 Evaluate
The topline advanced to Rs. 1122.50 millions, up 97.35% for the June 2025 quarter as against Rs. 568.80 millions during the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -67.00 millions as compared to Net Loss of Rs. -137.80 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 improved to 19.30% as compared to -66.90% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 1122.50 568.80 97.35 1122.50 568.80 97.35 3098.50 3596.00 -13.83
Other Income 49.50 38.00 30.26 49.50 38.00 30.26 166.20 249.10 -33.28
PBIDT 19.30 -66.90 -128.85 19.30 -66.90 -128.85 96.90 390.80 -75.20
Interest 60.00 32.10 86.92 60.00 32.10 86.92 154.60 137.80 12.19
PBDT -40.70 -99.00 -58.89 -40.70 -99.00 -58.89 -57.70 253.00 -122.81
Depreciation 47.70 50.80 -6.10 47.70 50.80 -6.10 202.90 210.90 -3.79
PBT -88.40 -149.80 -40.99 -88.40 -149.80 -40.99 -260.60 42.10 -719.00
TAX -21.40 -12.00 78.33 -21.40 -12.00 78.33 -108.30 6.60 -1740.91
Deferred Tax -21.40 -12.00 78.33 -21.40 -12.00 78.33 -108.30 0.20 -54250.00
PAT -67.00 -137.80 -51.38 -67.00 -137.80 -51.38 -152.30 35.50 -529.01
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 1.72 -11.76 -114.62 1.72 -11.76 -114.62 3.13 10.87 -71.22

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×